Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Next Previous
X
Search
Trial Profile

Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exicorilant (Primary) ; Enzalutamide
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Corcept Therapeutics

    • Most Recent Events

    • 03 May 2023 Status changed from active, no longer recruiting to completed.
    • 18 Feb 2023 Results ( as of July 7, 2022: n=39 of Phase 1 study) assessing efficacy and pharmacodynamic of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancerfrom presented at the 2023 Genitourinary Cancers Symposium
    • 30 Nov 2022 Planned End Date changed from 31 Dec 2024 to 31 Jan 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top